Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 TORONTO, ON — Zucara Therapeutics Inc., (“Zucara” or the… Read More
VANCOUVER, BC — /CNW/ — Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today… Read More
Numinus has submitted a Clinical Trial Application (CTA) to Health Canada to enable MDMA-assisted therapy Experiential Opportunities for practitioners as part of an investigational Phase 1 clinical trial. If approved, Numinus… Read More
First-of-its-kind distribution and warehouse center introduces a holistic approach to operations and energy management Facility poised to support United Therapeutics’ near-term growth objective of doubling its revenue run rate to… Read More
KIRKLAND, QC — Merck (NYSE: MRK), known as MSD outside the United States is proud to announce that Chantal Desbiens, Executive Director, Legal and Compliance & Chief Privacy Officer at Merck… Read More
